Origin Therapeutics Holdings (XCNQ:ORIG) EV-to-EBIT : 4.91 (As of Jun. 09, 2024)

Origin Therapeutics Holdings EV-to-EBIT Chart

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EV-to-EBIT	Get a 7-Day Free Trial				2.23	2.64	4.35	2.19	2.22

Competitive Comparison of Origin Therapeutics Holdings's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's EV-to-EBIT falls into.

Origin Therapeutics Holdings EV-to-EBIT Calculation

Origin Therapeutics Holdings's EV-to-EBIT for today is calculated as:

Origin Therapeutics Holdings's current Enterprise Value is C$-3.65 Mil.
Origin Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Origin Therapeutics Holdings  (XCNQ:ORIG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Origin Therapeutics Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Origin Therapeutics Holdings's Enterprise Value for the quarter that ended in Jun. 2023 was C$-1.65 Mil.
Origin Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Origin Therapeutics Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Origin Therapeutics Holdings (XCNQ:ORIG) Business Description